
The findings add new fodder for critics who say 340B has ballooned out of control with no corresponding benefit to patients. One hospital group called the report “another in a long line of misleading studies.”

The findings add new fodder for critics who say 340B has ballooned out of control with no corresponding benefit to patients. One hospital group called the report “another in a long line of misleading studies.”